Last reviewed · How we verify
NCT07164911: PrédicRéa
Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction
trial in HFrEF - Heart Failure With Reduced Ejection Fraction in 62 participants. Currently enrolling.
31 October 2027
Quick facts
| Lead sponsor | Centre Hospitalier de Corbie |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 25 November 2025 |
| Primary completion | 31 October 2027 |
| Estimated completion | 30 November 2027 |
| Sites | 1 location across France |
Conditions studied
- HFrEF - Heart Failure With Reduced Ejection Fraction — all drugs for HFrEF - Heart Failure With Reduced Ejection Fraction →
- Cardiac Rehabilitation — all drugs for Cardiac Rehabilitation →
- Exercise Training — all drugs for Exercise Training →
- Exercise Adaptations — all drugs for Exercise Adaptations →
Sponsor
Centre Hospitalier de Corbie
Who can join
Adults 40 to 75, any sex, with HFrEF - Heart Failure With Reduced Ejection Fraction or Cardiac Rehabilitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF). Change in VO₂peak (ΔVO₂peak), which serves as a prognostic marker for HFrEF engaged in exercise based cardiac rehabilitation program (ExCR). Responders to ExCR generally show improved cardiac function but some patients with HFrEF do not respond to ExCR. VO₂peak depends on three major components of oxygen transport: Pulmonary (lungs), circulatory (heart and vessels) and skeletal muscle (oxygen utilization) functions. These physiological responses to ExCR may be influenced by epigenetic regulation, specifically the expression of circulating microRNAs (c-miRNAs). Linking non-invasive measurements and epigenetic markers could 1) identify which component of the oxygen transport chain is most impaired and 2) allow personalized interventions to maximize VO₂peak improvements. The primary objective of this stidy is to assess the association between changes in VO₂peak during exercise training and circulating microRNA expression (miR-146a, miR-191, miR-23a, miR-140, miR-1, miR-21, miR-133a, miR-17-5p, miR-3200-3p). The secondary objective is to examine the relationship between pulmonary, cardiovascular, and neuromuscular adaptations to exercise and circulating microRNA expression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07164911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HFrEF - Heart Failure With Reduced Ejection Fraction
Currently open trials in the same condition.
- NCT06774014 — Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07164911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Corbie
- Last refreshed: 16 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07164911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing